Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Biosynex is a dynamic company specializing in the development, manufacturing, and distribution of rapid diagnostic tests. Operating within the healthcare sector, its primary function is to provide accessible, fast, and reliable testing solutions that cater to a broad spectrum of health conditions. This includes infectious diseases, pregnancy testing, and various other physiological disorders, supporting both clinical environments and end-user markets. Biosynex plays a crucial role in improving patient outcomes by enabling timely diagnostics, which are essential for early intervention and effective disease management. The company’s innovation in rapid testing technology places it at the forefront of diagnostic advancements, addressing an ever-growing demand for faster healthcare solutions. Furthermore, Biosynex's contributions are pivotal in public health management, aiding in the quick identification of outbreaks and facilitating informed decisions in epidemic or pandemic scenarios. As such, Biosynex is a significant player in the biotechnology industry, continually expanding its reach and impact through both research-driven and market-oriented strategies.
The business is unprofitable at the operating level (-66.54% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 5.9% YoY. Margins deteriorated 30.6pp alongside, both lines moving the wrong way.
ROIC dropped from -16.90% to -41.75%, capital efficiency is deteriorating. Negative free cash flow of -€9M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€95M
▼ -5.9% YoY
Net Income (TTM)
-€58M
▼ -34.0% YoY
Op. Margin
-66.54%
▼ -30.6pp YoY
ROIC
-41.75%
▼ -24.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€9M
▲ +42.7% YoY
Op. Cash Flow (TTM)
-€8M
▲ +43.1% YoY
Net Debt
€53M
Cash & Equiv.
€8M
3Y CAGR: -21.5%
Continue Research